A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Asthma

Treatments: Drug: PF-03526299; Drug: Fluticasone propionate; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00877539

A9291002

Details and patient eligibility

About

PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Enrollment: 29 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females 18-60 years
• Mild asthma
• Atopic to allergens

Exclusion criteria

• Unstable asthma
• Smokers or recent ex-smokers
• Recent allergen challenge

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

29 participants in 3 patient groups, including a placebo group

PF-03526299

Experimental group

Treatment:

Drug: PF-03526299

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Fluticasone propionate

Active Comparator group

Treatment:

Drug: Fluticasone propionate